AFT Licenses Maxigesic® IV in Brazil

AFT Pharmaceuticals (NZX: AFT, ASX: AFP) today announces the licensing of Maxigesic IV, the intravenous form of its proprietary pain relief medicine, for Brazil, the largest pharma market in South America and the tenth largest pharma market in the world 1.

AFT Pharmaceuticals Managing Director Dr Hartley Atkinson said: “We are delighted to announce our partnership with Brazil’s Halex Istar, an established hospital injectables focused company. It is the ideal partner for this market, the most significant in Latin America and one of the most important markets globally.”

Tiago Salinas, CEO of Halex Istar, said: “We are similarly excited to be establishing this partnership with AFT Pharmaceuticals, to be exclusively responsible for distributing its Maxigesic IV [Paracetamol with Ibuprofen] in Brazil. This helps Halex Istar to further strengthen its commitment to provide, to the Brazilian hospital pharmaceutical sector, innovative products of excellence. The medicine also complements our current multimodal analgesia portfolio”.

AFT has now out-licensing or its own distribution arrangements for Maxigesic IV in eight of the top Pharma markets in the world: USA, Germany, France, Italy, UK (AFT Pharma UK Ltd), Canada (AFT Pharma Canada Ltd), Spain and now Brazil. Dr Atkinson said, “We are pleased on the Maxigesic IV progress with launches now in 36 countries around the globe”.

Released for and on behalf of AFT Pharmaceuticals limited by Malcolm Tubby, Chief Financial Officer.

For more information:


Dr Hartley Atkinson
Managing Director
AFT Pharmaceuticals
Tel: +64 9488 0232

Richard Inder
The Project
Tel: +64 21 645 643